PTC Therapeutics, Inc. (PTCT) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

PTC Therapeutics, Inc. (PTCT) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

Seeking Alpha • Dec 4, 2025

PTC Therapeutics Swings to a Profit on $211 Million in Revenue — Is This Why a Major Fund Just Invested $32 Million?

California-based Palo Alto Investors increased its stake in PTCT by 456,144 shares in the third quarter, adding approximately $33.1 million in value. The change represents approximately 4.4% of reportable assets under management.

The Motley Fool • Dec 3, 2025

PTC Therapeutics, Inc. (PTCT) Discusses Progress in Small Molecule Splicing and Ferroptosis Platforms Transcript

PTC Therapeutics, Inc. (PTCT) Discusses Progress in Small Molecule Splicing and Ferroptosis Platforms Transcript

Seeking Alpha • Dec 3, 2025

Rare-Disease Biotech PTC Is Surging — And One Fund Just Raised Its Bet. Should You?

PTC's strong third quarter and breakout Sephience launch may help explain why one life-sciences fund is quietly upping its bet.

The Motley Fool • Dec 2, 2025

PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WARREN, N.J., Dec. 1, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on Nov. 24, 2025 , the company approved non-statutory stock options to purchase an aggregate of 2,000 shares of its common stock and 8,200 restricted stock units ("RSUs"), each representing the right to receive one share of its common stock upon vesting, to 15 new employees.

PRNewsWire • Dec 1, 2025

Cadrenal Therapeutics Appoints Dr. Lee Golden to Board of Directors

PONTE VEDRA, Fla., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing transformative therapeutics to overcome current gaps in anticoagulation therapy, today announced the appointment of Lee Scott Golden, M.D.

GlobeNewsWire • Dec 1, 2025

A PTC Therapeutics (PTCT) Insider Sold 10,000 Shares for $795,000

Emma Reeve recently exercised some PTC Therapeutics stock options and sold the shares immediately. Reeve is an independent board director at PTC Therapeutics.

The Motley Fool • Nov 29, 2025

Sandisk Set to Join S&P 500; Upwork, First Interstate BancSystem, PTC Therapeutics to Join S&P SmallCap 600

NEW YORK , Nov. 24, 2025 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P 500, S&P SmallCap 600:  S&P SmallCap 600 constituent Sandisk Corp. (NASD: SNDK) will replace The Interpublic Group of Companies Inc. (NYSE: IPG) in the S&P 500, and PTC Therapeutics Inc. (NASD: PTCT) will replace Sandisk in the S&P SmallCap 600 effective prior to the opening of trading on Friday, November 28. S&P 500 constituent Omnicom Group Inc. (NYSE: OMC) is acquiring The Interpublic Group of Companies in a deal expected to close soon, pending final conditions.

PRNewsWire • Nov 24, 2025

PTC Therapeutics to Host R&D Day

Event to take place on Dec. 2, 2025 in New York City WARREN, N.J. , Nov. 20, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that it will host an R&D Day to discuss its pipeline on Dec. 2, 2025, at 9:30 a.m.

PRNewsWire • Nov 20, 2025

This Fund Sold $30 Million in PTC Therapeutics Shares Amid a 93% Rally: Here's Why

New York City-based Armistice Capital sold 1,458,192 shares of PTC Therapeutics for an estimated $30.2 million in the third quarter. At quarter-end, Armistice reporting holding a total of nearly 3.3 million PTC Therapeutics shares valued at $201.1 million.

The Motley Fool • Nov 18, 2025